Mitoguazone
产品说明书
 |
同义名 : | Methylglyoxal-bis(guanylhydrazone); MGBG; Methyl-GAG |
| CAS号 : | 459-86-9 | |
| 货号 : | A995052 | |
| 分子式 : | C5H12N8 | |
| 纯度 : | 97% | |
| 分子量 : | 184.2 | |
| MDL号 : | MFCD00067519 | |
| 存储条件： |
Pure form Keep in dark place, inert atmosphere, 2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Mitoguazone, also known as Methylglyoxal-bis(guanylhydrazone), is a synthetic polycarbony derivative with potent antitumour activity. Mitoguazone is a brain-permeable, competitive inhibitor of SAMDC, which disrupts polyamine biosynthesis. Mitoguazone induces apoptosis. Mitoguazone inhibits the integration of HIV DNA into the cellular DNA of monocytes and macrophages. Mitoguazone has therapeutic potential for acute leukaemia, Hodgkin's lymphoma and non-Hodgkin's lymphoma[1][2][3][4].At concentrations as low as 0.5 μg/mL, Mitoguazone competitively inhibits spermine synthesis in lymphocytes. At concentrations of 30 μg/mL or higher, Mitoguazone inhibits protein synthesis and mitochondrial respiration[1].Mitoguazone induces apoptosis in Burkitt's lymphoma cell lines (Raji, Ramos and Daudi) and prostate carcinoma cell line (MPC 3), with apoptosis correlating with concentration and time, and induces p53-independent programmed cell death in human breast cancer MCF7 cell line[2]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
5.43mL 1.09mL 0.54mL |
27.14mL 5.43mL 2.71mL |
54.29mL 10.86mL 5.43mL |
